UNSPSC 51263128: Nipradilol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FVM336I71Y, chemically known as 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2h-1-benzopyran but generally known as nipradilol, which bears US NIH Compound Identifier 72006. European Medicines Agency schedules Nipradilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12423MIG.

UNSPSC 51263128 Nipradilol is a Commodity code for a specific pharmaceutical agent, though the recent state and local activity tagged under it reflects broader pharmaceutical procurement aligned with public health initiatives rather than nipradilol-specific sourcing. Seminole County, Florida and the Texas Health and Human Services Commission have posted opportunities that address naloxone acquisition and direct-to-manufacturer prescription programs respectively, both grounded in pharmacy benefit management and emergency pharmaceutical supply. The code sees activity from county health departments and state health agencies pursuing competitive pharmaceutical sourcing to support community health and pharmacy benefit programs. Work solicited includes procurement of finished pharmaceutical products (naloxone and safe drug deactivation systems in the Seminole County case) and exploratory contracting around direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels.

Recent activity concentrates in Florida and Texas. Seminole County, Florida posted an Invitation for Bid (IFB 60459723LAS) on June 30, 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford; the response deadline was July 26, 2023, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription contracting for self-insured employee and health plans, with no formal evaluation criteria or award values specified at the RFI stage. Both solicitations reflect state and local focus on pharmaceutical supply chain efficiency and cost management, though the code itself shows limited recent opportunities nationwide.